No Data
Suzhou Zelgen Biopharmaceuticals' ZG006 Drug Demonstrates Efficacy in Treating Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Market Cap up CN¥744m Last Week, Benefiting Both Individual Investors Who Own 31% as Well as Insiders
ZeJing Pharmaceutical's 2024 interim report
Summary of Zejing Pharmaceuticals' semi-annual report for 2024
Pharmaceutical company Zejing (688266.SH) released its performance for the first half of the year, with a net loss of 66.5361 million yuan.
Zejing Pharmaceuticals (688266.SH) has released its 2024 interim report, with a revenue of 2...
Zejing Pharmaceuticals (688266.SH): a net loss of 66.536 million yuan in the first half of the year, a decrease in losses compared to the same period last year.
On August 23, Zijing Pharmaceutical (688266.SH) released its semi-annual report, with revenue of 0.24 billion yuan, a year-on-year growth of 9.44%. The net loss was 66.536 million yuan, a decrease in losses compared to the previous year, and a non-GAAP net loss of 72.37 million yuan, a decrease in losses compared to the previous year. The basic earnings per share was -0.25 yuan.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Popularity With Investors Under Threat As Stock Sinks 29%No Data
